What the August 2026 Cases Actually Say About “Research Use Only” Sales
Status: August 14, 2026
THE KEY POINT
Eli Lilly has filed lawsuits against several companies selling retatrutide labeled or represented as “Research Use Only” (RUO).
However, Lilly's complaints do not simply argue:
Instead, Lilly alleges that these particular companies were actually intending and marketing retatrutide for human use, despite displaying RUO / “Not for Human Consumption” disclaimers.
Lilly attempts to prove objective intended human use from the total circumstances surrounding each company's sales and marketing.
THE FOUR IMPORTANT RUO CASES
1. LONE STAR PEPTIDE
RUO Position
- “Strictly for in vitro laboratory research use only”
- “Not for human or animal administration”
Evidence Lilly Alleges Contradicts That Position
- Retatrutide dosage calculator
- Target-dose calculations
- Bacteriostatic-water/reconstitution information
- Instructions calculating how much solution to draw
- Syringe-related information
- Dose-escalation information
- Human weight-loss/physiological discussions
- Founder social-media content discussing personal peptide/body-composition results
- Direct-to-consumer retail structure
Lilly's Theory
The surrounding instructions and marketing allegedly demonstrate that the product was intended to be administered by people rather than used exclusively for in-vitro research.
Important: The RUO disclaimer itself is acknowledged in Lilly's complaint. Lilly argues that the company's other conduct contradicts it.
2. ASTRA PEPTIDES
RUO Position
Products represented as being sold for research use.
Evidence Lilly Alleges Contradicts That Position
- “Wellness benefits of Retatrutide” marketing
- Appetite-suppression claims
- Fat-burning claims
- Insulin/metabolic claims
- Heart-health claims
- Human weight-loss discussions
- Reconstitution/dosing content
- Consumer reviews describing personal retatrutide use and weight loss
- Reviews allegedly describing assistance/support from Astra personnel
- Direct-to-consumer sales
Lilly's Theory
Astra allegedly knew consumers were personally using its products and marketed or supported them in a manner inconsistent with genuine laboratory-only use.
3. LEGENDARY PEPTIDES
RUO Position
Vials themselves state:
Evidence Lilly Alleges Contradicts That Position
- Consumer-oriented retatrutide kits
- Social-media marketing
- Customer reviews
- Co-founder allegedly discussing his own peptide “research”
- Discussion of increasing personal “dose and frequency”
- Discussion of physiological side effects
- Direct-to-consumer retail model
Lilly's Theory
Calling personal administration “research” does not make the activity laboratory research.
Important: This case demonstrates particularly clearly that Lilly does not consider an RUO statement printed on the vial dispositive when other evidence allegedly demonstrates human-use intent.
4. TEXAS PEPTIDES
RUO Position
Research-use disclaimers were present.
Evidence Lilly Alleges Contradicts That Position
- “Dramatic weight loss” advertising
- Appetite-reduction claims
- Blood-sugar-control claims
- Insulin-sensitivity claims
- Heart-health claims
- Cholesterol/blood-pressure claims
- Pain-management claims
- Consumer promotional pricing
- Direct links/instructions for consumers to purchase retatrutide
Lilly's Theory
Advertising the physiological and therapeutic benefits consumers can obtain from retatrutide allegedly demonstrates intended human use despite simultaneously displaying an RUO disclaimer.
WHAT LILLY APPEARS TO BE TARGETING
Across the complaints, Lilly repeatedly relies upon circumstances such as:
HIGH-RISK EVIDENCE ALLEGED BY LILLY
Human dosing information- Dose-escalation schedules
- “Units” or syringe calculations
- Injection/reconstitution instructions
- Bacteriostatic-water instructions connected with dosing
- Human weight-loss claims
- Appetite-suppression claims
- Therapeutic/health claims
- Before/after or personal-results content
- Customer testimonials describing self-administration
- Company representatives assisting personal users
- Founders/employees discussing their own peptide administration
- Consumer “kits” apparently configured for administration
- Marketing directed toward personal physical results
Lilly's theory is essentially:
RUO DISCLAIMER<br> +<br>OBJECTIVE EVIDENCE OF HUMAN-USE INTENT<br> ↓<br>ALLEGED UNAPPROVED HUMAN-USE DRUG DISTRIBUTION<br>
WHAT THESE LAWSUITS HAVE NOT YET ESTABLISHED
These complaints do NOT presently establish that:
None of the four RUO complaints appears to present the clean hypothetical of a supplier that:
- ✓ Sells solely for legitimate research/analytical purposes
- ✓ Makes no human therapeutic or weight-loss claims
- ✓ Provides no human dosing information
- ✓ Provides no injection instructions
- ✓ Provides no human dose calculator
- ✓ Does not promote customer testimonials involving personal use
- ✓ Does not encourage self-administration
- ✓ Does not provide personal-use support
- ✓ Actively rejects disclosed human-use purchases
- ✓ Genuinely directs products toward laboratory/nonclinical research
Lilly has not yet obtained a court ruling establishing that a bona fide research-only supplier fitting that fact pattern cannot sell retatrutide.
WHY “INTENDED USE” MATTERS
Federal drug regulation considers objective intended use, not merely the disclaimer printed on a product.
Under 21 CFR § 201.128, intended use can potentially be established from circumstances including:
- Labeling
- Advertising
- Statements by the seller or its representatives
- Product design/composition
- Circumstances surrounding distribution
Therefore:
is important evidence of intended use, but it does not automatically override contradictory conduct.
A court or regulator can examine the entire factual record.
RESEARCH-USE REGULATION ALSO MATTERS
21 CFR § 201.125 addresses certain drugs intended for research, analysis and testing.
This creates an important distinction between:
GENUINE RESEARCH DISTRIBUTION
Research material actually supplied and intended for legitimate nonclinical research, chemical analysis or physical testing.
versus
CONSUMER SALES DISGUISED AS RESEARCH
A product carrying an RUO disclaimer while surrounding marketing and distribution allegedly encourage personal administration.
Lilly is arguing that the defendants fall into the second category.
IMPORTANT: LILLY IS NOT THE FDA
Another major feature of these lawsuits is that Lilly generally isn't simply suing the defendants privately for “violating the FDCA.”
Instead, Lilly uses alleged unlawful drug distribution as the foundation for state unfair-competition and consumer-protection claims.
Its theory is broadly:
ALLEGEDLY UNLAWFUL HUMAN-USE RETATRUTIDE<br> ↓<br> UNFAIR COMPETITIVE CONDUCT<br> ↓<br> CONSUMER DIVERSION / COMPETITIVE INJURY<br> ↓<br> PRIVATE STATE-LAW CAUSE OF ACTION<br>
Lilly seeks remedies that can include:
- Injunctions
- Damages
- Disgorgement
- Statutory remedies
- Potential enhanced damages under applicable laws
- Other equitable relief
Whether Lilly can ultimately establish the required standing, causation, damages and elements of each state-law claim remains for the courts to determine.
STRIKER PHARMACY IS DIFFERENT
The Striker Pharmacy lawsuit should not be treated as an RUO test case.
Lilly alleges that Striker was compounding retatrutide for actual patients and supplying it as medication.
That is fundamentally different from a company claiming to sell a chemical exclusively for laboratory research.
